Quantcast
Home > Quotes > ATOS
ATOS

Atossa Genetics Inc. Common Stock (ATOS) Quote & Summary Data

$2.469
*  
0.041
1.63%
Get ATOS Alerts
*Delayed - data as of Jun. 22, 2018 13:33 ET  -  Find a broker to begin trading ATOS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ATOS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.43 / $ 2.47
1 Year Target
10
Today's High / Low
$ 2.55 / $ 2.43
Share Volume
166,315
50 Day Avg. Daily Volume
361,822
Previous Close
$ 2.51
52 Week High / Low
$ 19.0801 / $ 2.30
Market Cap
6,547,669
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.25

Special Dividend Data

Special Dividend
N/A
Special Dividend Date
Apr. 20, 2018
Special Dividend Payment Date
N/A

Intraday Chart

Shares Traded

Share Volume:
166,315
50 Day Avg. Daily Volume:
361,822

Trading Range

The current last sale of $2.469 is 7.35% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.55 $ 19.0801
 Low: $ 2.43 $ 2.30

Company Description (as filed with the SEC)

We are a clinical-stage pharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. We are developing Endoxifen with two routes of delivery: a topical formulation, applied like a lotion, for the treatment of a condition called mammographic breast density (or, MBD); and an oral formulation for breast cancer survivors who do not benefit from taking oral tamoxifen, a current FDA-approved standard of care. We are also developing our patented intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies and Chimeric Antigen Receptor T-cell therapies (CAR-T therapies), directly to the site of breast cancer. In 2017, we completed a Phase 1 clinical study of our proprietary oral and topical formulations of Endoxifen.  ... More ...  

Risk Grade

Where does ATOS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.50
Open Date:
Jun. 22, 2018
Close Price:
$ 2.51
Close Date:
Jun. 21, 2018

Consensus Recommendation

Analyst Info